With Its R&D On Track, GSK R&D Chair Slaoui Cites Individual Responsibility, Culture As Success Factors
By
Wendy Diller / Email the Author / “The Pink Sheet” DAILY Feb. 13, 2012
Word Count: 1228 / Article # 14120213005
Executive Summary
The Big Pharma did notably fewer deals in 2011, largely because of stringent criteria, reined in by a tight budget for R&D, but also because of its recent interest in external venture capital partners, some of which are not disclosed to the public.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.